Back to Search Start Over

Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival

Authors :
Josef Mueller-Hoecker
Nadja Herbach
Marc-Michael Zaruba
Stefan Brunner
Bruno C. Huber
Ruediger Wanke
Sebastian Grundmann
Rebekka Fischer
Gerald Assmann
Wolfgang-Michael Franz
Elisabeth Deindl
Robert David
Source :
Cardiovascular Research. 77:722-731
Publication Year :
2007
Publisher :
Oxford University Press (OUP), 2007.

Abstract

Aims An ongoing concept is that stem cells have the potential to regenerate the injured myocardium. In addition to direct vasorelaxing effects on the vasculature, which are mediated by an increased cAMP production leading to a decreased calcium influx in smooth muscle cells, parathyroid hormone (PTH) was recently shown to facilitate stem cell mobilization. Therefore, we analysed in a murine model of experimental myocardial infarction (MI) the influence of PTH treatment on survival, functional parameters, stem cell migration, and expression of vascular endothelial growth factor A (VEGF-A). Methods and results Mice (C57BL/6) were treated with PTH (80 µg/kg/d) for up to 14 days after coronary artery ligation. Functional and immunohistochemical analyses were performed at days 6 and 30 after MI. Stem cells and VEGF expression in the myocardium were analysed by FACS and qRT-PCR at day 2 after MI. PTH-treated animals revealed a significant improvement of post-MI survival and myocardial function that was related to a subsequent reduction of left ventricular wall thinning and scar extension. Infarcted hearts of PTH-treated mice revealed increased numbers of CD45+/CD34+ progenitor cells as well as an upregulation of VEGF-A mRNA associated with increased neovascularization and cell survival. Conclusions PTH application after MI increases migration of angiogenic CD45+/CD34+ progenitor cells to the ischaemic heart, which may attenuate ischaemic cardiomyopathy. As PTH is already used in patients with osteoporosis, our findings may have a direct impact on the initiation of clinical studies in patients with ischaemic heart disease.

Details

ISSN :
17553245 and 00086363
Volume :
77
Database :
OpenAIRE
Journal :
Cardiovascular Research
Accession number :
edsair.doi.dedup.....b545ba4eabab3f58c66417e4521f39a5
Full Text :
https://doi.org/10.1093/cvr/cvm080